EUCTR2015-000796-28-ES进行中（未招募）不适用
A pilot, single-blind, placebo-controlled study to assess efficacy and safety of interfascial blockade of the painful trapezius muscle in patients with fribromyalgia
Fundacio Clinic per a la Recerca Biomèdica0 个研究点开始时间: 2015年6月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age 18 or more
- •2.Patients diagnosed of Fibromyalgia as primary cause of pain, according ACR 1990 criteria
- •3.Not treated or on stable treatment for the last 3 months
- •4.Spontaneous continuous pain at the upper trapezius muscle for more than three months with a VAS intensity above 4,
- •5.Signed Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Any non-controlled condition or disease (cardiovascular, endocrine, etc)
- •2.Other neuromuscular, infectious, metabolic or inflammatory diseases.
- •3.Current anticoagulant therapy or coagulation abnormalities
- •4.Prior surgery at shoulder or spine level
- •5.Active vertebral disease (cervical or thoracic)
- •6.Joint or tendon disease affecting shoulder area
- •7.Intolerance or hypersensitivity to bupivacaine or other local anaesthetic agents
- •8.Pregnant or nursing women
- •9.Skin lesions at the injection site
- •10.Implantable devices for pain neuromodulation
- •11.Patients undergoing the procedure previously
研究者
相似试验
已完成
2 期
A single blind, placebo controlled pilot study to explore the safety and tolerability of a single oral dose of 30 mg BAY 1067197 in patients with chronic heart failure on the background of preexisting beta-blocker therapyheart failurecongestive heart failure10019280NL-OMON38750Bayer10
进行中（未招募）
1 期
Pilot study to assess the safety of BAY 1067197 in stable heart failure patients on standard therapy including ß-blockerMedDRA version: 16.1 Level: LLT Classification code 10019279 Term: Heart failure System Organ Class: 100000004849Heart failureEUCTR2013-001287-34-NLBayer HealthCare AG11
已完成
不适用
A double-blind, placebo-controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction and lower urinary tract symptomsMen with LUTS and BPE/BOOUrological and Genital DiseasesBenign prostatic obstruction and lower urinary tract symptomsISRCTN71613863Plethora Solutions Limited (UK)88
进行中（未招募）
不适用
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - NAThis study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in line with Americian Association recommendations.MedDRA version: 8.1Level: LLTClassification code 10055026Term: Prostatic obstructionEUCTR2006-002055-32-DEPlethora Solutions Limited80
进行中（未招募）
1 期
A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) - PSD506-OAB-004benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS)MedDRA version: 8.1 Level: LLT Classification code 10055026 Term: Prostatic obstructionEUCTR2006-002055-32-IEPlethora Solutions Limited80